RE: RE: RE: RE: testing timeline example
SEDAR has all of the News Releases for PharmaGap. I quickly scanned the NR's up to Dec 31 2006, and couldn't find another reference to Oregon. (However, it is late, and I might have missed something. If anybody has the initiative to look more closely at the NRs in the clear light of day, please do so)
The NRs are a goldmine for information. This one particularly caught my attention:
PharmaGap Launches Licensing Program for Lead Cancer Drug PhGalpha1
Ottawa, Ontario/June 19, 2006 – PharmaGap Inc. (TSX-V: GAP) ("PharmaGap" or "the Company") announced that the process led by Dundee Securities Corporation ("Dundee") and Wellington West Capital ("Wellington West") to sell or license its lead cancer drug compound has been officially launched, with a focused approach to pharmaceutical companies, biotech firms, in-licensing firms and others with a stated interest in the treatment of cancer through cell signaling processes. The business model adopted by PharmaGap at the start of 2005 is to develop compounds through to proof of principle in animal models and to out-license successive products prior to commencement of clinical trials. Based on success to date in animal trials, PharmaGap believe that this is the opportune time to out-license the Company’s first product.
The Company expects that this process should be completed in the course of the next four to six months.
During the course of this process, the Company will be undertaking a continuing series of animal testing designed to support the value of PhGalpha1, in colon, lung, and ovarian cancers. Test results will be available incrementally over the next several months, with initial results expected within the next 60 days.
At the Company’s Annual General Meeting held on June 15, Robert McInnis, the President and C.E.O. of PharmaGap, reported on a number of significant advances made during the course of the past year, including:
? a refocusing of the business on being a provider of pre-clinical product to the pharmaceutical industry
? successful completion of the Company’s first animal trials, showing efficacy and low toxicity of PhGalpha1 in colon and breast cancer types, as well as in reducing the effects of Multi Drug Resistance in traditional cancer therapy
? the launching of the sale or licensing program outlined above
? the filing of three provisional patents for its lead drug compound and drug development architecture
Mr. McInnis stated "The momentum inside the Company to produce successive drug compounds to treat a range of cancers through the mechanisms of the cell signaling processes has been building through the year, and the successful testing program for PhGalpha1 adds to the basis for development of successive products, using the same proprietary drug architecture.
"The pharmaceutical industry itself has continued to evolve toward a model of drug compound acquisition and in-licensing and away from primary reliance on development of products internally. The sourcing of the Big Pharma pipeline – the source of the next "blockbuster" drug – is more and more seen to be from firms such as PharmaGap, We are optimistic the sale and licensing program led by Dundee and Wellington West will result in significant value to PharmaGap from our lead compound."
About PharmaGap Inc.:
PharmaGap Inc. (TSX-V: GAP), based in Ottawa, ON, is a biotechnology company with a core focus on developing novel therapeutic compounds for the treatment of cancer. PharmaGap's research platform targets cellular signalling pathways controlled by Protein Kinase C (PKC) isoforms. PharmaGap's lead drug compound, PhGalpha1, is in preclinical development and targets PKCalpha. The Company's strategy is to out-license drug compounds to larger life sciences companies at the preclinical stage. For more information on PharmaGap please visit the Company's website at www.pharmagap.com.
For information relating to this Release, please contact:
Robert McInnis, President & CEO
(613) 990-9551 bmcinnis@pharmagap.com
Interesting, eh?